If you make or sell hemp-derived cannabinoid products, this is the brief your operations and QA teams need, without the market commentary.
The provision
Section 781 of Public Law 119-37, effective “365 days after the enactment of this Act”. The Act was signed 12 November 2025, so the operative date is 12 November 2026.
It amends Section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o), replacing the definition of hemp.
The two tests you are now working to
Test one, on plant material and derivatives. Hemp means Cannabis sativa L. and its parts “with a total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid) of not more than 0.3 percent on a dry weight basis”. The previous federal test measured delta-9 only.
Test two, on finished products. Final hemp-derived cannabinoid products are excluded from the definition if they contain “greater than 0.4 milligrams combined total per container” of total THC including THCA, plus “any other cannabinoids that have similar effects (or are marketed to have similar effects)… as a tetrahydrocannabinol (as determined by the Secretary of Health and Human Services)”.
Four clauses that decide your SKU list
A final hemp-derived cannabinoid product falls outside the definition if it contains any of the following.
Cannabinoids not capable of being naturally produced by the plant. Cannabinoids that are capable of being naturally produced but “were synthesized or manufactured outside the plant”. More than 0.4 mg combined total per container as above. And separately, intermediate products “marketed or sold as a final product or directly to an end consumer for personal or household use”.
Run your SKU list against all four, not just the milligram cap. In our experience most reformulation plans clear one clause and fail another, usually the synthesized-outside-the-plant one.
Why “per container” changes the arithmetic
The cap attaches to the container, defined by the innermost retail packaging, not to the serving. A multi-piece pack is assessed on its total contents.
This is the difference between a reformulation problem and a category problem. Reducing per-unit dose does not help if the pack count keeps the container total above the line, and 0.4 mg is below a single conventional serving in most formats.
The sequence that works
1. Inventory at finished-goods level, per pack size. Not per formula. The cap is per container, so two pack sizes of the same formula can land differently.
2. Re-test on the right method. Total THC including THCA, on a cannabinoid panel wide enough to capture minors that might fall under the “similar effects” clause. A COA reporting delta-9 against 0.3 percent answers the old question. Our note on COA, SDS and TDS documentation sets out what each document is actually good for.
3. Requalify inputs. Ask each supplier which test their COAs report against, whether they will issue total-THC documentation, and what residual cannabinoid content their material carries as a number. The 12-point supplier checklist covers the wider set.
4. Decide reformulate, reposition or withdraw, per SKU. Only after steps one to three, because doing it first is guesswork.
5. Restart stability. Any formulation change invalidates your existing shelf-life evidence. Stability testing is usually the longest pole in this tent, which is why it should start early rather than last.
On the proposed delay
The Senate Appropriations Committee released continuing resolution text on 2 August 2026 that would move most of these restrictions to 11 December 2026. As of 3 August 2026 it had not passed the Senate, had not passed the House, and had not been signed.
Reporting on the text indicates it would not cover cannabinoids incapable of being naturally produced by the plant. And it does not touch state law, where separate dates apply, including Illinois restrictions taking effect 12 November under state law.
Four weeks does not accommodate testing turnaround plus supplier requalification plus packaging lead time. Plan to November.
What is not affected
Non-cannabinoid hemp. The statute defines industrial hemp separately and protects stalk and fiber, grain, seed, oil, cake, nut and hull uses, microgreens and edible leaf from immature plants, research plants not entering commerce, and viable seed from compliant genetics.
Terpenes are not cannabinoids and are not reached by any of the four clauses. That has direct consequences for how you think about sourcing routes, particularly if a reformulated product will be carrying its aromatic profile without a cannabinoid alongside it.
About this brief
Written 3 August 2026 and checked against the statute and the Federal Register rather than against secondary coverage. This is a summary for commercial planning, not legal advice. Where the answer depends on your product format, your state or your licence position, take the specific question to your own counsel.
